Clinical trial NCT06249451: Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
Official title: SAB-Support-Study: Can Checklist-based Phone Calls Improve the Quality of Staphylococcus Aureus Bacteraemia (SAB) Management
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Staphylococcus Aureus Bacteremia
Keywords: Staphylococcus aureus
Bacteremia
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
First posted: 2024-02-08
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The main objective of this study is to investigate whether checklist-based close telephone consultation and process surveillance for S. aureus bacteraemia (SAB) can improve adherence to our in-house SAB-guidelines (prospective quality- improvement group).

In addition, the effects of telephone consultation on the clinical outcome of patients will be examined.


Eligibility criteria: Inclusion Criteria:

* ≥ 18 years
* Inpatient treatment at the University Medicine Greifswald university hospital
* First diagnosis of SAB in hospital

Exclusion Criteria:

* SAB already known before admission
* Palliative management within 48 hrs after SAB diagnosis
* Death within 48 hrs after SAB diagnosis
* Hospital discharge within 48hrs after SAB diagnosis

Primary outcomes:
measure: SOP adherence, calculated as a sum score per patient with the following 8 parameters:
timeFrame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Secondary outcomes:
measure: Time to specific antimicrobial treatment according to guidelines concerning agent and duration
timeFrame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)
measure: Time to negativity of follow up blood cultures
timeFrame: Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis)
measure: Time till TEE is performed (when indicated)
timeFrame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)
measure: Length of hospital stay after SAB diagnosis
timeFrame: Day of SAB diagnosis until hospital discharge (no later than day 90 after diagnosis)
measure: In-hospital mortality (all patients)
timeFrame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)
measure: In-hospital mortality (because of SAB complications)
timeFrame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)
measure: Hospital readmission until day 30 after SAB diagnosis (all patients)
timeFrame: Day of SAB diagnosis until day 30 after diagnosis
measure: Hospital readmission until day 30 after SAB diagnosis (because of SAB complications)
timeFrame: Day of SAB diagnosis until day 30 after diagnosis
measure: Hospital readmission until day 90 after SAB diagnosis (all patients)
timeFrame: Day of SAB diagnosis until day 90 after diagnosis
measure: Hospital readmission until day 90 after SAB diagnosis (because of SAB complications)
timeFrame: Day of SAB diagnosis until day 90 after diagnosis
measure: 90-day all-cause mortality
timeFrame: Day of SAB diagnosis until day 90 after diagnosis
measure: 90-day mortality because of SAB complications
timeFrame: Day of SAB diagnosis until day 90 after diagnosis
measure: Relapse of bacteremia until day 90 after diagnosis
timeFrame: Day of SAB diagnosis until day 90 after diagnosis
measure: Quality of discharge summary (documentation and treatment plan), calculated as a sum score
timeFrame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)
measure: Infectious diseases consultation, when indicated (yes/no)
timeFrame: Hospital admission until hospital discharge (no later than day 90 after diagnosis)
Other outcomes:
Locations:
city: Greifswald
country: Germany
facility: Greifswald University Medicine
Study officials:
References: